|
**Overview**: Phospholipid Syndrome Panel**Introduction**: The Phospholipid Syndrome Panel is a diagnostic tool designed for comprehensive antiphospholipid screening using serum samples. In India, APS causes ~15-20 percent of recurrent miscarriages and significant young-onset strokes/DVTs, requiring full laboratory criteria (lupus anticoagulant + anti-cardiolipin + anti-beta2GP) for diagnosis. High morbidity from incomplete testing in rural/low-SES patients with obstetric or thrombotic events, limited multi-assay labs, delayed warfarin/LMWH leading to catastrophic APS or fetal wastage. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs immunoassay for anti-cardiolipin IgG/IgM, beta-2 glycoprotein IgG/IgM, lupus anticoagulant, phosphatidylserine IgG/IgM, and DRVVT over 1-2 days with high accuracy, valuable for meeting Sydney criteria. This diagnostic falls under autoimmune screening and targets patients with thrombosis, miscarriage, or SLE, addressing accurate detection to guide lifelong anticoagulation or obstetric management. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling full APS profiling and reducing thrombotic/obstetric burden. Its serum-based approach ensures reliable multi-antibody evaluation.**Other Names**: PL Syndrome Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Comprehensive APS panel standard; in India, expanding in rheumatology/thrombosis centers.**Purpose**: The test assesses 8 parameters including anti-cardiolipin IgG to guide comprehensive APS screening, confirm criteria, inform anticoagulation.**Test Parameters**: 1. Anti-Cardiolipin IgG, 2. Anti-Cardiolipin IgM, 3. Beta-2 Glycoprotein IgG, 4. Beta-2 Glycoprotein IgM, 5. Lupus Anticoagulant, 6. Phosphatidylserine IgG, 7. Phosphatidylserine IgM, 8. DRVVT.**Pretest Condition**: No fasting required; patients should have thrombosis or miscarriage.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on thrombosis, miscarriage, SLE.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected APS including catastrophic events, benefits of comprehensive screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or anticoagulants can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Multiple positive antibodies confirm APS, necessitating specialist input.**Specialist Consultation**: Hematologists/rheumatologists should be consulted for management.**Additional Supporting Tests**: Repeat testing in 12 weeks for confirmation.**Test Limitations**: Affected by anticoagulants; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Thrombosis Studies India 2023. |
